<DOC>
	<DOCNO>NCT00996125</DOCNO>
	<brief_summary>This study design evaluate immunogenicity safety GlaxoSmithKline Biologicals ' human papillomavirus ( HPV ) vaccine pre-teen adolescent female subject age 9 - 17 year . One group subject receive HPV vaccine group receive control .</brief_summary>
	<brief_title>Immunogenicity Safety Study GSK Biologicals ' Human Papillomavirus 580299 Vaccine Healthy Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR ) comply requirement protocol . Healthy Chinese female include 9 17 year age time first vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject inform assent obtain subject , appropriate , prior enrolment . Healthy subject establish medical history historydirected clinical examination enter study . Subjects must pregnant . Absence pregnancy verify urine pregnancy test vaccination . Subjects must either nonchildbearing potential , childbearing potential , must abstinent practiced adequate contraception 30 day prior vaccination , negative pregnancy test agree continue precaution 2 month completion vaccination series . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day ( i.e. , Days 029 ) first dose vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . A subject planning become pregnant , likely become pregnant planning discontinue contraceptive precaution study period two month last vaccine dose . Pregnant breastfeeding . Subjects must least three month postpregnancy breastfeed enter study . Previous vaccination HPV plan administration HPV vaccine foreseen protocol study period . Previous administration component study vaccine . History chronic condition ( ) require treatment cancer autoimmune disease . History allergic disease , suspect allergy reaction likely exacerbate component vaccine . Hypersensitivity latex . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period .</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Human papillomavirus</keyword>
	<keyword>China</keyword>
	<keyword>HPV vaccine</keyword>
</DOC>